Skip to content
10-Q

Quarterly Report

EPIRUS Biopharmaceuticals, Inc.

0001104659-15-059110

← back to feed
Filed
Aug 12, 2015 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2015 · Aug 10, 2015 23.57M sh
Capex Q2 2015 · Jun 30, 2015 $46K
Capex Q2 2015 · Jun 30, 2014 $35K
Long Term Debt Q2 2015 · Jun 30, 2015 $13.92M
Long Term Debt Q2 2015 · Dec 31, 2014 $7.28M
Short Term Debt Q2 2015 · Jun 30, 2015 $896K
Cash And Equivalents Q2 2015 · Jun 30, 2015 $58.29M
Cash And Equivalents Q2 2015 · Dec 31, 2014 $21.46M
Cash And Equivalents restated Q2 2015 · Jun 30, 2014 $25.58M
Cash And Equivalents restated Q2 2015 · Dec 31, 2013 $1.8M
Stockholders Equity Q2 2015 · Jun 30, 2015 $59.11M
Stockholders Equity Q2 2015 · Dec 31, 2014 $32.4M
Current Liabilities Q2 2015 · Jun 30, 2015 $9.73M
Current Liabilities Q2 2015 · Dec 31, 2014 $7.38M
Current Assets Q2 2015 · Jun 30, 2015 $59.41M
Current Assets Q2 2015 · Dec 31, 2014 $23.02M
Total Assets Q2 2015 · Jun 30, 2015 $87.48M
Total Assets Q2 2015 · Dec 31, 2014 $51.39M
Sga Expense Q2 2015 · Jun 30, 2015 $6.78M
Sga Expense Q2 2015 · Jun 30, 2015 $10.95M
Sga Expense restated Q2 2015 · Jun 30, 2014 $6.36M
Sga Expense restated Q2 2015 · Jun 30, 2014 $9.08M
Rd Expense Q2 2015 · Jun 30, 2015 $8.28M
Rd Expense Q2 2015 · Jun 30, 2015 $11.35M
Rd Expense restated Q2 2015 · Jun 30, 2014 $2.59M
Rd Expense restated Q2 2015 · Jun 30, 2014 $6.09M
Net Income Q2 2015 · Jun 30, 2015 −$15.29M
Net Income Q2 2015 · Jun 30, 2015 −$22.81M
Net Income restated Q2 2015 · Jun 30, 2014 −$9.89M
Net Income restated Q2 2015 · Jun 30, 2014 −$17.51M
Operating Income Q2 2015 · Jun 30, 2015 −$15.01M
Operating Income Q2 2015 · Jun 30, 2015 −$22.24M
Operating Income restated Q2 2015 · Jun 30, 2014 −$8.95M
Operating Income restated Q2 2015 · Jun 30, 2014 −$15.17M